Current Atherosclerosis Reports

Papers
(The TQCC of Current Atherosclerosis Reports is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
APOA1: a Protein with Multiple Therapeutic Functions77
Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients73
Social Determinants of Health and Cardiovascular Disease: Current State and Future Directions Towards Healthcare Equity67
COVID and Cardiovascular Disease: What We Know in 202167
Food Insecurity and Cardiovascular Disease Risk65
Periodontal Inflammation and the Risk of Cardiovascular Disease63
Trimethylamine N-Oxide (TMAO), Diet and Cardiovascular Disease60
CD36 in Atherosclerosis: Pathophysiological Mechanisms and Therapeutic Implications57
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis56
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?53
High-Density Lipoproteins and Serum Amyloid A (SAA)51
Time-Restricted Eating to Improve Cardiovascular Health45
A Review of the Relationship Between CTRP Family and Coronary Artery Disease43
Lipid Lowering Drugs: Present Status and Future Developments42
The Role of the Gut Microbiota in Coronary Heart Disease41
The Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review40
New Pharmacological Approaches to Target PCSK940
Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions39
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician39
Microparticles (Exosomes) and Atherosclerosis38
Statins and Inflammation37
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets36
The Association Between Periodontitis and Cardiovascular Disease: an Update36
Women Living with Familial Hypercholesterolemia: Challenges and Considerations Surrounding Their Care35
The Long Non-coding Road to Atherosclerosis34
Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia33
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond32
More than Just a Monolayer: the Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis32
Phytosterols and Cardiovascular Disease32
Exosomes: Multifaceted Messengers in Atherosclerosis31
Digital Health Innovations to Improve Cardiovascular Disease Care31
Clinical Pharmacology of Statins: an Update30
Targeting Inflammation to Reduce Residual Cardiovascular Risk29
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues28
HDL-small RNA Export, Transport, and Functional Delivery in Atherosclerosis27
Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications27
Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials26
Menopausal Hormone Therapy: a Comprehensive Review26
Bempedoic Acid: for Whom and When26
Overweight, Obesity, and CVD Risk: a Focus on Visceral/Ectopic Fat25
Nutrition and Gastrointestinal Microbiota, Microbial-Derived Secondary Bile Acids, and Cardiovascular Disease25
Alcohol Consumption and Cardiovascular Disease Risk: Placing New Data in Context25
Understanding Immigration as a Social Determinant of Health: Cardiovascular Disease in Hispanics/Latinos and South Asians in the United States24
The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia24
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?24
High HDL-Cholesterol Paradox: SCARB1-LAG3-HDL Axis24
Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics23
Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors23
Structural Basis for Vital Function and Malfunction of Serum Amyloid A: an Acute-Phase Protein that Wears Hydrophobicity on Its Sleeve23
Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis22
Apolipoprotein E and Atherosclerosis22
Statins in a Distorted Mirror of Media22
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease21
Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment21
The Difference Between High Density Lipoprotein Subfractions and Subspecies: an Evolving Model in Cardiovascular Disease and Diabetes21
Wall Shear Stress Alteration: a Local Risk Factor of Atherosclerosis20
Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis20
Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease19
Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents19
Dyslipidemia Management in Pregnancy: Why Is It not Covered in the Guidelines?19
Nutrient Profiling Systems, Front of Pack Labeling, and Consumer Behavior19
Lipoprotein (a): When to Measure and How to Treat?18
Ambient Air Pollution and Atherosclerosis: Recent Updates18
RNA Silencing in the Management of Dyslipidemias18
Spontaneous Coronary Artery Dissection: Latest Developments and New Frontiers18
The Genetic Basis of Hypertriglyceridemia18
Lipid Phenotypes and DNA Methylation: a Review of the Literature17
Inclisiran: How Widely and When Should We Use It?17
Lp(a): a New Pathway to Target?17
LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective17
Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease17
MicroRNAs and Circular RNAs in Lipoprotein Metabolism17
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?17
The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis16
Metabolomic Biomarkers of Healthy Dietary Patterns and Cardiovascular Outcomes16
The Role of Statins in Current Guidelines16
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men16
Obesity Management in Cardiometabolic Disease: State of the Art16
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis16
Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?16
Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)15
Contributions of Food Environments to Dietary Quality and Cardiovascular Disease Risk15
Managing Ischemic Heart Disease in Women: Role of a Women’s Heart Center15
Inflammatory Links Between Hypertriglyceridemia and Atherogenesis15
The Role of High-Density Lipoprotein Cholesterol in 202215
Novel RNAi-Based Therapies for Atherosclerosis15
Ultra-processed Foods and Cardiometabolic Health Outcomes: from Evidence to Practice15
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management14
Dietary Influences on Atherosclerotic Cardiovascular Disease Risk14
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?14
Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well14
Gene-Environment Interactions for Cardiovascular Disease14
The Role of Sex-Specific Risk Factors in the Risk Assessment of Atherosclerotic Cardiovascular Disease for Primary Prevention in Women14
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–202014
Sex Differences in Coronary Atherosclerosis14
0.28122711181641